vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average – Should You Sell?

vTv Therapeutics Inc. (NASDAQ:VTVT) shares crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $33.93 and traded as low as $33.21. vTv Therapeutics shares last traded at $35.08, with a volume of 94,154 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have recently commented on VTVT shares. Zacks Research lowered vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. BTIG Research restated a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen raised vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Evercore began coverage on vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price objective on the stock. Finally, Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Trading Down 4.7%

The company has a 50 day moving average price of $33.93 and a 200 day moving average price of $35.59. The firm has a market cap of $138.22 million, a PE ratio of -37.72 and a beta of 0.27.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analysts’ expectations of $20.00 million. As a group, equities research analysts anticipate that vTv Therapeutics Inc. will post -2.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Several large investors have recently made changes to their positions in the business. Baker BROS. Advisors LP boosted its stake in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the last quarter. Geode Capital Management LLC increased its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the period. 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at $731,000. Finally, Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the fourth quarter valued at about $221,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.